
 
 
 
 
 
 
 
 
   
 1. A human C-type lectin comprising the amino acid sequence YX1-X2M, wherein X1 and X2 may be any amino acid residue, X1 and X2 being the same or different from one another.  
 
     
 2. A human C-type lectin according to claim 1, characterised in that X1 and X2 are S.  
 
     
 3. A human C-type lectin according to claim 1 or 2, characterised in that the human C-type lectin is essentially of myeloid cellular origin.  
 
     
 4. A human C-type lectin according to any of the claims 1 -3, characterised in that the human C-type lectin comprises an amino acid sequence comprising the amino acid residues 1 - 10 of SEQ ID N0:2.  
 
     
 5. A human C-type lectin according to any of the claims 1 -4, characterised in that the human C-type lectin comprises an amino acid sequence having a homology of at least 97% with the amino acid sequence of SEQ ID NO:2.  
 
     
 6. A human C-type lectin according to any of the claims 1 -5, characterised in that the human C-type lectin comprises the amino acid sequence of SEQ ID NO:2.  
 
     
 7. A nucleic acid molecule encoding a human C-type lectin according to any of the claims 1 - 6.  
 
     
 8. A nucleic acid molecule according to claim 7, characterised in that the nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:1.  
 
     
 9. A binding molecule capable of specifically binding to the human C-type lectin according to any of the claims 1 - 6.  
 
     
 10. A binding molecule according to claim 9, characterised in that it is a human binding molecule.  
 
     
 11. A binding molecule according to claim 9 or 10, characterised in that it is a scFv or IgG molecule.  
 
     
 12. A binding molecule according to any of the claims 9 -11, characterised in that the binding molecule comprises at least a CDR3 region comprising the amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID      NO:4 and SEQ ID NO:5.  
 
     
 13. A binding molecule according to any of the claims 9 -12, characterised in that the binding molecule comprises a heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9 and SEQ ID NO:11.  
 
     
 14. A functional variant of a binding molecule according to any of the claims 9 - 13, characterised in that the functional variant is capable of competing for specifically binding to the human C-type lectin according to any of the claims 1 - 6.  
 
     
 15. An immunoconjugate comprising a binding molecule according to any of the claims 9 - 13 or a functional variant according to claim 14, the immunoconjugate further comprising at least one tag.  
 
     
 16. An immunoconjugate according to claim 15, characterised in that the tag is selected from the group consisting of a toxic substance, a radioactive substance, a liposome, an enzyme and combinations thereof.  
 
     
 17. A nucleic acid molecule encoding a binding molecule according to any of the claims 9 - 13 or a functional variant according to claim 14.  
 
     
 18. A vector comprising at least one nucleic acid molecule according to claim 7 or 8 or at least one nucleic acid molecule according to claim 17.  
 
     
 19. A host comprising at least one vector according to claim 18.  
 
     
 20. A host according to claim 19, characterised in that the host is a cell derived from a human cell.  
 
     
 21. A method of producing a human C-type lectin according to any of the claims 1 - 6 or a binding molecule according to any of the claims 9 - 13 or a functional variant according to claim 14, wherein the method comprises the steps of:   a) Culturing a host according to claim 19 or 20 under conditions conducive to the expression of the human C-type lectin, binding molecule or functional variant, and optionally, b) recovering the expressed human C-type lectin, binding molecule or functional variant.  
 
     
 22. A human C-type lectin, binding molecule or functional variant as obtainable by the method according to claim 21.  
 
     
 23. A method of identifying a binding molecule specifically binding to the human C-type lectin according to any of the claims 1 - 6 or a nucleic acid molecule according to claim 7 or 8, wherein the method comprises the steps of:   a) contacting a phage library of binding molecules with material comprising the human C-type lectin according to any of the claims 1 - 6, b) selecting at least once for a phage binding to the material comprising the human C-type lectin according to any of the claims 1 - 6, and c) separating and recovering the phage binding to the material comprising the human C-type lectin according to any of the claims 1 - 6.  
 
     
 24. A method of obtaining a binding molecule specifically binding to the human C-type lectin according to any of the claims 1 - 6 or a nucleic acid molecule according to claim 7 or 8, wherein the method comprises the steps of:   a) performing the method according to claim 23, and b) isolating from the recovered phage the binding molecule and/or the nucleic acid molecule encoding the binding molecule.  
 
     
 25. A composition comprising a human C-type lectin according to any of the claims 1 - 6 or 22, a binding molecule according to any of the claims 9 - 13 or 22, a functional variant according to claim 14 or 22, or an immunoconjugate according to claim 15 or 16.  
 
     
 26. A composition comprising a nucleic acid molecule according to claim 7, 8 or 17.  
 
     
 27. A pharmaceutical composition comprising a human C-type lectin according to any of the claims 1 - 6 or 22, a binding molecule according to any of the claims 9 - 13 or 22, a functional variant according to claim 14 or 22, an immunoconjugate according to claim 15 or 16, or a composition according to claim 25 or 26, the pharmaceutical composition further comprising at least one pharmaceutically acceptable excipient.  
 
     
 28. A pharmaceutical composition according to claim 27 further comprising at least one other therapeutic agent.  
 
     
 29. A human C-type lectin according to any of the claims 1 - 6 or 22, a binding molecule according to any of the claims 9 - 13 or 22, a functional variant according to claim 14 or 22, an immunoconjugate according to claim 15 or 16, a composition according to claim 25 or 26, or a pharmaceutical composition according to claim 27 or 28 for use as a medicament.  
 
     
 30. A human C-type lectin according to any of the claims 1 - 6 or 22, a binding molecule according to any of the claims 9 - 13 or 22, a functional variant according to claim 14 or 22, an immunoconjugate according to claim 15 or 16, a composition according to claim 25 or 26, or a pharmaceutical composition according to claim 27 or 28 for use in the diagnosis, prevention, treatment, or combination thereof, of a neoplastic disorder or disease.  
 
     
 31. Use of a human C-type lectin according to any of the claims 1 - 6 or 22, a binding molecule according to any of the claims 9 - 13, a functional variant according to claim 14 or 22, an immunoconjugate according to claim 15 or 16, a composition according to claim 25 or 26, or a pharmaceutical composition according to claim 27 or 28 in the preparation of a medicament for the diagnosis, prevention, treatment, or combination thereof, of a neoplastic disorder or disease.  
 
     
 32. Use according to claim 31, wherein the neoplastic disorder or disease is selected from the group consisting of acute myeloid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, acute promyelocytic leukemia, myelodysplastic syndrome, juvenile myelomonocytic leukemia, and Langerhans cell histiocytosis.  
 
     
 33. A method of detecting a human C-type lectin according to any of the claims 1 - 6, wherein the method comprises the steps of:   a) contacting a sample with a diagnostically effective amount of a binding molecule according to any of the claims 9 - 13 or 22, or a functional variant according to claim 14 or 22, and b) determining whether the binding molecule or functional variant specifically binds to a compound of the sample.  
 
     
 34. A method for selecting myeloid cells comprising the steps of:   a) contacting a sample comprising myeloid cells with a binding molecule capable of specifically binding to a human C-type lectin according to any of the claims 1 - 6, b) separating the cells that bind to the binding molecule from the cells that do not bind to the binding molecule, and c) recovering the cells which are bound by the binding molecule.  
 
     
 35. A method according to claim 34, characterised in that the sample is contacted, before, during or after contact with a binding molecule capable of specifically binding to a human C-type lectin according to any of the claims 1 - 6, with at least a second binding molecule, wherein the second binding molecule binds to an antigen other than the human C-type lectin according to any of the claims 1 - 6.  
 
     
 36. A method according claim 34 or 35, characterised in that the binding molecule capable of specifically binding to a human C-type lectin according to any of the claims 1 - 6 is labeled with a detectable label.  
 
   
 
 
 
 
 
 
 
 
